Skip to main content
SpringerLink
Log in

The US FDA has received a report of a patient who died within 24 hours of receiving fingolimod [Gilenya].

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. FDA.FDA Drug Safety Communication: Safety review of a reported death after the first dose of Multiple Sclerosis drug Gilenya (fingolimod). Internet Document: 20 Dec 2011. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The US FDA has received a report of a patient who died within 24 hours of receiving fingolimod [Gilenya].. React. Wkly. 1383, 4 (2012). https://doi.org/10.2165/00128415-201213830-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213830-00012

Keywords

Search

Navigation